- Published at
- by smallcaps.com.au
mixed
mixed
Prescient Therapeutics Moves Advanced PTX-100 Cutaneous T-Cell Lymphoma Therapy Closer to Commercialisation
Prescient Therapeutics (ASX: PTX) is fast emerging as the newest developer of an advanced cancer drug to meet a significant market need, potentially